Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study

PHASE4CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

June 30, 2008

Study Completion Date

December 31, 2008

Conditions
Subarachnoid HemorrhageCerebral Vasospasm
Interventions
DRUG

Eicosapentaenoic acid ethyl ester

Orally administered 900 mg eicosapentaenoic acid ethyl ester three times a day (2700 mg ⁄ day) from the surgery next day to 30 days after the onset of SAH.

Trial Locations (5)

803-8543

Ootemachi Hospital, Kitakyushu

060-8570

Nakamura Memorial Hospital, Sapporo

020-8505

Iwate Medical University, Morioka

980-8574

Tohoku University, Sendai

755-8505

Yamaguchi University Hospital, Ube

All Listed Sponsors
collaborator

Nakamura Memorial Hospital

OTHER

collaborator

Iwate Medical University

OTHER

collaborator

Tohoku University

OTHER

collaborator

Ootemachi Hospital

UNKNOWN

lead

Yamaguchi University Hospital

OTHER

NCT00839449 - Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study | Biotech Hunter | Biotech Hunter